World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
79
Citations
27354
World Ranking
17430
National Ranking
8724

Ulka N. Vaishampayan publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Ulka N. Vaishampayan sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 1,026 publications — 95th percentile

95% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Ulka N. Vaishampayan D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Ulka N. Vaishampayan sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 79 D-Index — 14th percentile

14% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Ulka N. Vaishampayan is affiliated with the University of Michigan-Ann Arbor in the United States. Their research spans several areas within medicine, with significant focus on oncology, molecular biology, and cancer research. The scholar has contributed extensively to the study and treatment of renal and related cancers, prostate cancer, and cancer immunotherapy, among other fields.

The main fields of study for Vaishampayan include Medicine and Biochemistry, Genetics and Molecular Biology. Subfields prominently covered in their work are Pulmonary and Respiratory Medicine, Oncology, Molecular Biology, Cancer Research, and Surgery.

The topics frequently addressed in their research comprise:

  • Renal cell carcinoma treatment
  • Cancer Immunotherapy and Biomarkers
  • Prostate Cancer Treatment and Research
  • Cancer Genomics and Diagnostics
  • Renal and related cancers
  • Bladder and Urothelial Cancer Treatments
  • Radiopharmaceutical Chemistry and Applications

Vaishampayan has published in a variety of journals, with frequent appearances in:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • Regular and Young Investigator Award Abstracts
  • Clinical Cancer Research
  • The Journal of Urology

Notable recent papers include:

  • "Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer," 2021, Nature
  • "First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer," 2021, Annals of Oncology
  • "A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial," 2021, The Lancet
  • "Phase 1 study of single-agent WNT974, a first-in-class Porcupine inhibitor, in patients with advanced solid tumours," 2021, British Journal of Cancer
  • "A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma," 2020, British Journal of Cancer

Frequent co-authors collaborating with Vaishampayan include:

  • Sumanta K. Pal
  • Toni K. Choueiri
  • Ajjai Alva
  • Elisabeth I. Heath
  • Michael Staehler

Best Publications

  • Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.

    Arjun V. Balar;Matthew D. Galsky;Jonathan E. Rosenberg;Thomas Powles

  • Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial

    Robert J. Motzer;Brian I. Rini;David F. McDermott;Bruce G. Redman

  • External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study

    Daniel Y.C. Heng;Wanling Xie;Meredith M. Regan;Lauren C. Harshman

  • Intermittent versus continuous androgen deprivation in prostate cancer.

    Maha Hussain;Catherine M. Tangen;Donna L. Berry;Celestia S. Higano

  • Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: Multicohort, open-label phase II KEYNOTE-199 study

    Emmanuel S. Antonarakis;Josep M. Piulats;Marine Gross-Goupil;Jeffrey Goh;Jeffrey Goh

  • Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial

    David C. Smith;Matthew R. Smith;Christopher Sweeney;Aymen A. Elfiky

  • Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma

    Toni K. Choueiri;Ulka Vaishampayan;Jonathan E. Rosenberg;Theodore F. Logan

  • Cytoreductive Nephrectomy in Patients with Synchronous Metastases from Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium

    Daniel Y.C. Heng;J. Connor Wells;Brian I. Rini;Benoit Beuselinck

  • Trastuzumab, Paclitaxel, Carboplatin, and Gemcitabine in Advanced Human Epidermal Growth Factor Receptor-2/neu–Positive Urothelial Carcinoma: Results of a Multicenter Phase II National Cancer Institute Trial

    Maha H.A. Hussain;Gary R. MacVicar;Daniel P. Petrylak;Rodney L. Dunn

  • Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial

    Andrew J Armstrong;Susan Halabi;Tim Eisen;Samuel Broderick

  • Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

    Thomas Powles;Michiel S van der Heijden;Daniel Castellano;Matthew D Galsky

  • Randomized Phase II Study of Erlotinib Combined With Bevacizumab Compared With Bevacizumab Alone in Metastatic Renal Cell Cancer

    Ronald M. Bukowski;Fairooz F. Kabbinavar;Robert A. Figlin;Keith Flaherty

  • The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study

    Jenny J. Ko;Wanling Xie;Nils Kroeger;Jae lyun Lee

  • Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial

    Michael B Atkins;Elizabeth R Plimack;Igor Puzanov;Mayer N Fishman

  • Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study

    Lucia Nogova;Lecia V. Sequist;Jose Manuel Perez Garcia;Fabrice Andre

  • Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder : Prognostic significance and comparative analysis in primary and metastatic tumors

    Rafael E. Jimenez;Maha Hussain;Fernando J. Bianco;Ulka Vaishampayan

  • Combination Paclitaxel, Carboplatin, and Gemcitabine Is an Active Treatment for Advanced Urothelial Cancer

    Maha Hussain;Ulka Vaishampayan;Wei Du;Bruce Redman

  • A Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Hormone-Refractory Metastatic Prostate Cancer

    Elisabeth I. Heath;David W. Hillman;Ulka Vaishampayan;Shijie Sheng

  • Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy.

    Rana R. McKay;Nils Kroeger;Nils Kroeger;Wanling Xie;Jae Lyun Lee

  • Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations.

    Sumanta K. Pal;Jonathan E. Rosenberg;Jean H. Hoffman-Censits;Raanan Berger

Frequent Co-Authors

Toni K. Choueiri
Toni K. Choueiri Harvard University
Jonathan E. Rosenberg
Jonathan E. Rosenberg Memorial Sloan Kettering Cancer Center
Joaquim Bellmunt
Joaquim Bellmunt Beth Israel Deaconess Medical Center
David F. McDermott
David F. McDermott Beth Israel Deaconess Medical Center
Thomas Powles
Thomas Powles Queen Mary University of London
Maha Hussain
Maha Hussain Northwestern University
Brian I. Rini
Brian I. Rini Vanderbilt University Medical Center
Sun Young Rha
Sun Young Rha Yonsei University
Emmanuel S. Antonarakis
Emmanuel S. Antonarakis University of Minnesota
Cora N. Sternberg
Cora N. Sternberg Cornell University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you're considering a career in medicine or healthcare, exploring related online degrees can expand your opportunities and flexibility. Many students find that not all roles in healthcare require attending traditional, in-person medical school. For example, a healthcare administration accelerated degree can fast-track your path to leadership positions in hospitals or clinics, with programs designed for working professionals and career changers alike.

For nurses aiming to become Family Nurse Practitioners, rn to fnp programs offer online bridge options that streamline the journey from an Associate Degree in Nursing to a Master of Science in Nursing.

Nutrition also plays a vital role in health. A bachelor's in nutrition online prepares graduates for careers in dietetics, wellness coaching, and community health without needing to relocate or pause employment.

If your interests lie in healthcare management, pursuing cahme-accredited online mha programs ensures you receive a quality education recognized by employers, opening doors to senior administrative roles nationwide.

Best Scientists Citing Ulka N. Vaishampayan

Trending Scientists

Recently Published Articles